|
Report:
Lead
Sponsor: 
Translating
microbiome futures
Gaspar Taroncher-Oldenburg, Susan
Jones, Martin Blaser, Richard Bonneau, Peter Christey,
José C Clemente, Eran Elinav, Elodie Ghedin, Curtis
Huttenhower, Denise Kelly, David Kyle, Dan Littman,
Arpita Maiti, Alexander Maue, Bernat Olle, Leopoldo
Segal, Johan E T van Hylckama Vlieg & Jun Wang
A group of microbiome researchers discuss some of the
challenges in developing a new generation of microbiome
therapies.
MICROBIOME THERAPEUTICS
Applying
hologenome theory to define and apply molecules derived
from the skin microbiome to treat human disease
Rich Gallo, Professor and Founding Chair, Department of
Dermatology, University of California San Diego
Impact of the gut
microbiome in shaping innate immunity: Defining
mechanisms
Kathy McCoy, Professor and Scientific Director of the
International Microbiome Centre, University of Calgary
Unraveling microbiome signatures for drug design, PK, and
PD
Matthew Henn, Executive Vice President, Microbiome
R&D, Seres Therapeutics
**
Awaiting Permission To Release **
Translating the Challenges of Developing
Microbiome-Based Therapeutics: The Rebiotix Story
Edward Burd, Head of Regulatory Affairs, Rebiotix
Pharmacological Mimicry of Gastric Bypass Microbiome to
Treat Obesity
David Beno, Chief Scientific Officer, Xeno Biosciences
** Awaiting Permission To Release
**
Therapeutic
Targeting of the Gut Microbiome with Symbiotic Drugs
Ward Peterson, President & CEO, Symberix
Standardization
vs. innovation in microbiome discovery: studying our
most vulnerable populations illuminates the way
Heloise Breton, Product Manager, DNA Genotek
Protecting
Inventions in the Microbiome Space: Challenges and
Strategies
Olga A. Partington, Associate, Sterne, Kessler, Goldstein
& Fox P.L.L.C
GUT MICROBIOME
Microbiota-mediated
defense against intestinal infection
Eric Pamer, Head, Division of Subspeciality Medicine &
Director, The Lucille Castori Center for Microbes,
Inflammation & Cancer, Memorial Sloan Kettering Cancer
Center
Building the
leading Microbiome-derived Immunotherapy Company
Pierre Belichard, CEO, Enterome
Opportunities and challenges in clinical applications of
microbiome profiling
Dan Knights, CEO, CoreBiome
**
Awaiting Permission To Release **
Gut feeling: function based microbiome
research
Jan Majta, Bioinformatician Microbiome Research, Ardigen
Harnessing the Therapeutic Potential of Commensal Microbes
for the Treatment of Human Epilepsy
Anthony Colasin, CEO and Founder, Bloom Science
** Awaiting Permission To Release
**
The Asian gut microbiome, a new
therapeutics discovery opportunity
Jonathan Krive, CEO, AsiaBiome
SKIN MICROBIOME
Positioning
Microbiome: Analysis for use in Precision Medicine
Morten Isaksen, Founder & CEO, Bio-Me
The Cinco de Mayo
Study: A One-Year Longitudinal Study of the Facial Skin
Microbiome in Normal Healthy Adults
Kausar Malik, Senior Principal Research Scientist, Amway
Corporation
How the
microbiome and clean beauty are shaking up the beauty
industry
Elsa Jungman, Founder and CEO, ELSI Skin Health
You’ve collected your microbiome samples – now what?
Nur Hasan, CSO, CosmosID
**
Awaiting Permission To Release **
Flexible Panel-Based Solutions for
Pathogen Detection using Spatial Multiplexing on
Nanofluidic qPCR Platform
Nitin Puri, Associate Director, Infectious Disease, Thermo
Fisher Scientific
Building the
Evidence in Microbiome Based Therapies
Emma Taylor, CEO & Co-Founder, Naked Biome
Human Microbiota:
Proof of Concept to Production
Işil Tüzün Weber, Process Engineer Technical Operations
Manufacturing, SynCo Bio Partners
MatriSys
Bioscience – new developments
Mark Wilson, CEO, MatriSys Bioscience Inc
Adaptation of
the gut microbiome and clinical outcomes in improving
lactose tolerance
Andrew Ritter, CEO, Ritter Pharmaceuticals
Dermocosmetic
strategies to rebalance the skin’s ecosystem
David Herault, Global R&D Director Bioactives, BASF
The complete
microbiome workflow: Towards future diagnostic and
clinical solutions
Madhuri Jasti, Scientist III, Thermo Fisher Scientific
PROBIOTICS CONGRESS
Mechanisms
involved in the prevention of type I diabetes onset by
Lactobacillus johnsonii N6.2
Graciela Lorca, Associate Professor, Department of
Microbiology and Cell Science, University of Florida
ProbioSatys – Naturally modulating the
appetite via the microbiome
Grégory Lambert, CEO & Vice President of R&D,
TargEDys
HOWARU® Shape
- a probiotic/synbiotic with benefits beyond weight
management
Johanna Maukonen, Technology Leader, Global Health &
Nutrition Science, DuPont Nutrition &
Health, Finland
Probiotics: Beyond Gut Health
Anurag Pande, Vice President – Scientific Affairs, Sabinsa
Corporation
**
Awaiting Permission To Release **
To count or not to count? Pros and
Cons of probiotic enumeration methods
Marco Pane, R&D Director, Probiotical Healthcare
Viability of
cells in commercial and homemade probiotics
Sandra Buerger, Lecturer of Natural Sciences &
Mathematics, Boston University
Microbiota
Changes in Elderly and Potential Implications in Cancer
and other Chronic Diseases
Gabriela Riscuta, Program Director, Nutritional Science
Research Group, Division of Cancer Prevention, National
Cancer Institute
Metabolic
Reconditioning – A microbiome-based weight loss solution
Kiran Krishnan, Chief Science Officer, Microbiome Labs,
LLC.
Microbiome
Metabolites: Understanding Microbial Function Within the
Host
Danielle Demers, Business Development Natural Products,
AnalytiCon Discovery LLC
Rescuing the Lost Infant Microbiome: Back from the Brink
David Kyle, Chief Scientific Officer, Evolve Biosystems
** Awaiting Permission To Release
**
Bifidobacterium, breastfeeding, and
infant health
Diana Taft, Postdoctoral Research Fellow, Mills Lab,
University of California Davis
Personalized
Nutrition using gut microbiome and clinical data
Tali Raveh-Sadka, Director of Research, DayTwo
The Essential
Ingredients for Decoding the Microbiome with
Metabolomics
Geoffrey Feld, Senior Study Director, Metabolon
Microbiome Opportunities- A Seventure View of the
Scientific and Commercial Landscape
Denise Kelly, Venture Partner and Investment Advisor,
Seventure
**
Awaiting Permission To Release **
The influence of fiber structure on the
structure and function of colonic microbiota
Stephen Lindemann, Assistant Professor of Food and the
Human Microbiome, Purdue University
|
|
